Conmed (CNMD) Tops Q2 EPS by 1c; Lowers FY22 Guidance

Conmed (NYSE: CNMD) reported Q2 EPS of $0.76, $0.01 better than the analyst estimate of $0.75. Revenue for the quarter came in at $277.2 million versus the consensus estimate of $274.25 million.

GUIDANCE:

Due to changes in foreign exchange rates, the Company is lowering its revenue guidance for the full year 2022 and now expects revenue between $1.095 billion and $1.140 billion compared to its prior guidance of between $1.105 billion and $1.150 billion. Based on recent exchange rates, the Company now expects foreign exchange to have a 100 to 150 bps negative impact on full-year 2022 revenue growth.

The Company now expects full-year 2022 adjusted diluted net earnings per share in the range of $3.40 to $3.55, down from the prior range of $3.50 to $3.65 to account for a $0.10 currency headwind.

For earnings history and earnings-related data on Conmed (CNMD) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance